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Abstract
Background: Cryptococcus neoformans is commonly associated with meningoencephalitis in immunocompromised
patients and occasionally in apparently healthy individuals. Recurrence of infection after initial treatment is not
uncommon. We studied C. neoformans isolates from 7 Cuban patients with recurrent cryptococcal meningitis.
Antifungal susceptibility and genotyping with microsatellite molecular typing were carried out.
Methods: Isolates (n = 19) were recovered from cerebrospinal fluid, blood, urine and semen. Antifungal
susceptibilities for amphotericin B, fluconazole, flucytosine, itraconazole, voriconazole, posaconazole and
isavuconazole were tested by CLSI M27A3 broth microdilution method. Genotyping was done using a panel of 9
microsatellite (STR) markers: (CT)n, (TG)n, (TA)n, (CTA)n, (TCT)n, (CCA)n, (TTAT)n, (ATCC)n and (TATT)n.
Results: The average number of isolates/patient was 2.71. The mean time interval between the collection of any
two isolates was 52.5 days. All strains were identified as C. neoformans var. grubii (serotype Aa). Although none of
the strains were resistant to the studied drugs, in serial isolates from two patients, MICs values of triazoles
increased 4-5 log2 dilutions over time. STR patterns showed 14 distinctive profiles. In three patients the recurrent
infection was associated with genotypically identical isolates. The four other patients had relapse isolates which
were genotypically different from the initial infecting strain.
Conclusion: Recurrences of cryptococcal meningitis in our series of patients was not associated with development
of drug resistance of the original strain but by an initial infection with different strains or a reinfection with a new
strain.
Background
The incidence of cryptococcosis started to increase with
the beginning of the acquired immune deficiency syn-
drome (AIDS) epidemic in the early 1980 s. Its fre-
quency declined in the Western world since the mid
1990 s due to the use of highly active antiretroviral ther-
apy (HAART). However, cryptococcal meningitis is still
one of the most common life-threatening opportunistic
fungal infections in immunocompromised patients, par-
ticularly among those with AIDS in Sub-Saharan Africa
[1] and Asia [2]. These patients show a high tendency to
relapse despite effective antifungal therapy. Early studies
performed with karyotyping and restriction fragment
length polymorphism (RFLP) analysis of serial isolates of
AIDS patients in New York concluded that recurrent
infection was caused through persistence of the original
strain and not from infection with new strains [3,4]. A
later study using the same typing technique but with
isolates from AIDS patients from Uganda found that
among 17 patients with more than 1 cerebrospinal fluid
(CSF) isolate of Cryptococcus neoformans, sequential iso-
lates were identical or highly related in 12 patients [5].
Several treatment strategies have been used in patients
with cryptococcal meningitis but the optimum regimen
is still not clear. Amphotericin B with or without flucy-
tosine remain the agents of choice for induction therapy
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while fluconazole has proven to be superior for long-
term maintenance therapy [6,7]. High dose fluconazole
with flucytosine is an oral treatment alternative although
this regimen is not as effective as amphotericin B and
flucytosine [8]. Different molecular typing methods have
been used in the epidemiological analyses of clinical
and/or environmental isolates of C. neoformans, includ-
ing electrophoretic karyotyping, PCR fingerprinting, ran-
dom amplified polymorphic DNA analysis, RFLP
analysis, MLST and amplified fragment length poly-
morphism analysis with divergent results [9-11]. To
determine whether recurrences of cryptococcal meningi-
tis in seven Cuban patients were due to development of
drug resistance or to infection by multiple strains, we
tested the in vitro antifungal susceptibility and deter-
mined the genotypes of the sequential isolates using a
recently described microsatellite based assay [12].
Methods
Fungal isolates
From the stock collection of the mycology laboratory at
the Instituto de Medicina Tropical “Pedro Kourí” (IPK)
in Havana, Cuba, 19 clinical isolates of C. neoformans
from patients with recurrent infection were selected for
this study. The isolates were recovered at different time
intervals from cerebrospinal fluid (n = 16), blood, urine
and semen (one each) from 7 patients (6 HIV positive
and 1 HIV negative) admitted at the institute between
1995 and 2001, just before HAART was introduced in
Cuba (Table 1). All patients were admitted to the clini-
cal AIDS care division at the IPK. Initial isolates were
obtained at diagnosis and before any antifungal therapy
was used and follow up isolates were from patients dur-
ing or after treatment with antifungal drugs. Repeat
lumbar puncture was only performed in those cases
which did not react within two weeks of therapy or
those who showed a clinical deteriorisation during or
after treatment. From each culture positive sample a sin-
gle isolate from morphological similar colonies was
archived. Species identification was initially done by
growth on canavanine-glycine-bromothymol blue (CGB)
agar and strains were stored in sterile water at room
temperature until the study was carried out. From initial
isolation until the study the isolates were typically sub-
cultured between 4 and 6 times. Before use, the identifi-
cation of all isolates was repeated with a commercial
identification system (Auxacolor 2; Bio-Rad, Marnes-la-
Coquette, France).
Antifungal agents and susceptibility testing
Broth microdilution testing was performed in accordance
with Clinical and Laboratory Standards Institute docu-
ment M27-A3 guidelines [13]. Standard antifungal pow-
ders of amphotericin B (Sigma, The Netherlands),
flucytosine (Valeant Pharmaceuticals, The Netherlands),
fluconazole (Pfizer Central Research, U.K.), itraconazole
(Janssen-Cilag, The Netherlands), voriconazole (Pfizer
Central Research, U.K.), posaconazole (Schering Plough,
USA), and isavuconazole (Basilea Pharmaceutica,
Switzerland) were used. The stock solutions of the drugs
were prepared in the appropriate solvent. The final con-
centrations of the antifungal agents were 0.016 to 8 μg/
mL for amphotericin B, itraconazole, voriconazole, and
posaconazole; 0.063 to 32 μg/mL for flucytosine and flu-
conazole; and 0.004 to 4.00 μg/mL for isavuconazole.
After 72 h incubation at 35°C the minimum inhibitory
concentration (MIC) was defined as the lowest concen-
tration of drug showing absence of growth for amphoter-
icin B and a prominent reduction of growth (≥50%) for
the other antifungal agents compared to the drug-free
growth control. The MICs were read optically and spec-
trophotometrically at 420 nm after agitation. Candida
parapsilosis ATCC 22019 and C. krusei ATCC 6258 were
used as quality control [13].
Mating-, sero- and genotyping
C. neoformans isolates were grown on Sabouraud’s dex-
trose agar at 30°C for 48 h and DNA was obtained from
freshly grown cells using a MagNA lyser/MagNA Pure
protocol (Roche Diagnostics, Almere, the Netherlands).
The mating- and serotype was determined using four
different PCRs that specifically amplify the mating-type
a or a allele of the STE20 locus for either serotype A or
D isolates [14]. The reference isolates CBS9172 (aA),
CBS8710 (aA), CBS10511 (aD) and CBS10513 (aD)
were included as positive control for each of the four
PCRs.
STR analysis was performed in two steps as described
previously [12]: i) Amplification of STR loci by PCR:
three separate multiplex PCRs were used (CNA2,
CNA3, and CNA4, respectively), each amplifying three
different STRs. For every multiplex PCR, one of the
amplification primers was labelled with carboxyfluores-
cein (FAM), hexachlorofluorescein (HEX), or tetrachlor-
ofluorescein (TET) at the 5’ end, respectively. In
addition to the amplification primers (concentrations
according to reference [11]), each PCR mixture con-
tained 0.2 mM deoxynucleoside triphosphates, 1 U of
FastStart Taq DNA polymerase (Roche Diagnostics), 2
mM MgCl2 and 1 ng of genomic DNA in 1 × reaction
buffer. Thermocycling was performed in a T1 thermocy-
cler (Biometra, Göttingen, Germany) by using the fol-
lowing thermal protocol: 10 min of denaturation at 95°
C, followed by 35 cycles of 30 s of denaturation at 95°C,
30 s of annealing at 60°C, and 1 min of extension at 72°
C. Before the reaction mixtures were cooled to room
temperature, an additional incubation for 10 min at 72°
C was performed. All temperature transitions were
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performed with maximal heating and cooling settings (5°
C/s). ii) Detection and sizing of amplification products
with subsequent assignment of repeat numbers: the
fragments obtained were combined with the ET550-R
size standard (GE Healthcare, Diegem, Belgium) and
analyzed on a MegaBACE 500 automated DNA platform
(GE Healthcare), according to the instructions of the
manufacturer. Electropherograms were analyzed using
Fragment Profiler 1.2 software (GE Healthcare). Identi-
cal isolates were those that possessed alleles with the
same number of repeat units in all nine loci. Consistent
with the previous separation of genotypes into microsa-
tellites complexes (MC’s), isolates with genotypes that
differed in up to two loci were considered to be geneti-
cally related [12]. Genotypes differing in more than two
loci were considered to be unrelated. The study was
approved by the Scientific Council and Ethics Commit-
tee of the Instituto Pedro Kouri, Havana, Cuba.
Results
The majority of strains were obtained from HIV positive
patients, except those recovered from patient 7 for whom
no underlying disease could be demonstrated (Table 1).
The mean number of isolates/patient was 2.71 (range 2-4
isolates/patients). The mean time between collection of
any two isolates was 52.5 days (range 13-123 days). All
Table 1 Clinical data, origin and date of isolation of the studied strains
Patient
Nr.
Sex HIV/
Year of diagnosis
Sample Isolation
date
Interval between each
isolate in days
(number)
Total of days Antifungal
treatment
1 Male +/1991 Blood 14/04/95 0
(08-36-09-92)
0 AmB+Flu
Flu (maintenance)
CSF 14/04/95 0
(08-36-09-75)
0 AmB+Flu
Flu (maintenance)
CSF 18/07/95 96
(08-36-10-01)
96 AmB+Flu
2 Male +/1990 CSF 05/09/95 0
(08-36-09-97)
0 Flu+Itr
Urine 08/12/95 95
(08-36-09-70)
95 Flu
CSF 10/01/96 34
(08-36-09-91)
129 Flu
3 Female +/1994 CSF 18/01/96 0
(08-36-09-71)
0 AmB+Flu
Flu (maintenance)
CSF 29/02/96 34
(08-36-09-72)
34 AmB+Flu
4 Male +/1995 CSF 23/04/97 0
(08-36-09-82)
0 AmB+FC+Flu
CSF 06/05/97 14
(08-36-09-89)
14 AmB+FC+Flu
5 Male +/1998 CSF 15/04/00 0
(08-36-09-24)
0 AmB
Flu (maintenance)
CSF 26/10/00 194
(08-36-09-25)
194 AmB+FC
6 Female +/1996 CSF 12/06/00 0
(08-36-10-56)
0 AmB+FC
Flu (maintenance)
CSF 12/10/00 123
(08-36-10-52)
123 AmB
Flu (maintenance)
CSF 30/10/00 19
(08-36-10-53)
142 AmB+FC
7 Male - CSF 09/01/01 0
(08-36-09-26)
0 AmB+Itr
Flu (maintenance)
CSF 17/04/01 99
(08-36-09-30)
99 AmB+Flu
Flu (maintenance)
CSF 07/06/01 52
(08-36-09-78)
151 Flu+Itr
Semen 19/06/01 13
(08-36-09-42)
164 Liposomal AmB
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patients received antifungal treatment but only the
HIV negative patient (nr. 7) survived. All clinical
strains were identified as C. neoformans var. grubii ser-
otype A and mating-type a.
For the antifungal susceptibility testing, no differences
between visual and spectrophotometric readings were
observed, and the MICs for the quality control strains
were all within the suggested reference ranges (data not
shown). Table 2 summarizes the in vitro susceptibilities
of the isolates according to the origin of the strains.
When all data were considered together, the widest
ranges and highest MICs were for fluconazole (0.25 to 8
μg/mL) and flucytosine (0.5 to 8 μg/mL) and the lowest
were for isavuconazole, voriconazole, and posaconazole.
Amphotericin B, posaconazole and isavuconazole exhib-
ited similar MICs patterns among all the studied iso-
lates. Isolates from patients 6 and 7 exhibited a stepwise
increase among serial isolates for some of the drugs.
Increased MICs values of at least 4 log2 dilutions over
the time for fluconazole, itraconazole, voriconazole and
isavuconazole were observed in patient 6. In patient 7
higher MICs were found between initial and last isolate
for fluconazole (4 log2), itraconazole (6 log2) and vorico-
nazole (5 log2). Amphotericin B, flucytosine and posaco-
nazole demonstrated maximally only a 1-3 log2 difference
among serial isolates.
STR patterns of the 19 isolates showed 14 distinct
profiles. Three patients (patients 2, 3 and 6) had genoty-
pically identical isolates over the course of time. The
serial isolates from patient 6 were genotypically identical
but also showed the largest difference in MIC for the
triazoles including drugs which have not been used
(itraconazole, voriconazole, isavuconazole). The other
four patients were probably infected by more than one
genotype (Figure 1) although this might be biased
because from each positive CSF culture only one colony
was archived for future study.
Discussion
No previous studies of the antifungal susceptibility and
genetic diversity of sequential isolates of C. neoformans
obtained from individual patients have been done in
Cuba. Here we studied 19 serial clinical strains of C.
neoformans from 7 patients with recurrent cryptococcal
meningitis during the pre-HAART period by analyzing
their antifungal susceptibility and molecular profiles.
Our results on the in vitro activities of the main anti-
fungal drugs are similar to those published previously
[15-17]. Amphotericin B has long successfully been used
to treat various yeasts and mould infections. In this ser-
ies there was only one log2 dilution difference between
the sequential isolates with a highest observed MIC of
Table 2 Minimum inhibitory concentration of all C. neoformans var. grubii isolates for seven antifungal drugs
Patient Nr. Strain
Nr.
Minimum Inhibitory Concentration (μg/mL) reading at 72 h
AmB FC Flu Itr Vor Pos Isa
1 08-36-09-92 0.125 8 4 0.125 0.016 0.125 0.016
08-36-09-75 0.25 2 4 0.063 < 0.016 0.063 < 0.004
08-36-10-01 0.25 4 4 0.25 0.125 0.125 < 0.004
2 08-36-09-97 0.125 2 1 0.031 0.063 0.125 < 0.004
08-36-09-70 0.25 2 2 0.063 0.063 0.125 0.016
08-36-09-91 0.125 1 1 0.031 < 0.016 0.063 0.008
3 08-36-09-71 0.25 2 2 0.063 0.063 0.016 0.016
08-36-09-72 0.125 8 2 0.125 0.125 0.031 < 0.004
4 08-36-09-82 0.25 2 2 0.031 0.031 0.031 0.008
08-36-09-89 0.25 1 4 0.031 0.125 0.063 0.008
5 08-36-09-24 0.25 2 1 < 0.016 < 0.016 0.016 0.004
08-36-09-25 0.25 1 0.25 0.031 < 0.016 0.016 < 0.004
6 08-36-10-56 0.125 0.5 0.25 < 0.016 < 0.016 0.063 < 0.004
08-36-10-52 0.125 0.5 4 0.125 0.125 0.016 0.031
08-36-10-53 0.25 1 8 0.125 0.25 0.016 0.063
7 08-36-09-26 0.25 0.5 0.5 < 0.016 < 0.016 0.031 0.016
08-36-09-30 0.25 0.5 0.5 0.031 0.031 0.016 0.004
08-36-09-78 0.125 1 1 0.031 0.063 0.016 < 0.004
08-36-09-42 0.25 4 8 0.5 0.25 0.031 < 0.004
Abreviations: AmB: amphotericin B, FC; flucytosine, Flu; fluconazole, Itr; itraconazole, Vor; voriconazole, Pos; posaconazole, Isa; isavuconazole.
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0.25 μg/mL way below the suggested breakpoint for
resistance of MIC ≥2 μg/mL, which was found to be
associated with therapeutic failure [18]. All flucytosine
MICs were < 16 μg/mL which are regarded as suscepti-
ble [7,14]. Among the azoles, fluconazole showed the
lowest in vitro activity. In fact, previous reports have
already demonstrated the low activity of this drug
against C. neoformans isolates, even though it has pro-
ven to be more active in vivo [19]. According to these
authors, the good therapeutic results obtained are lar-
gely attributable to its high concentrations in cerebrosp-
inal fluid. Although no resistance has been found in the
present collection of isolates (MIC < 16 μg/mL) [20], a
stepwise increase of 4 and 5 dilutions was found in 2
patients suggesting development of reduced levels of
antifungal susceptibility [7]. In one patient (nr. 6) the
sequential isolates were genotypically identical. Of inter-
est is the finding that the increase of fluconazole MICs
over time in patients 6 and 7 parallels data with itraco-
nazole, voriconazole and isavuconazole but not with
posaconazole. These observations support previous work
that suggests the development of cross-resistance of flu-
conazole with other triazoles [20]. Isavuconazole is an
experimental broad-spectrum antifungal triazole active
against clinically relevant yeasts and moulds [21]. Our
results are in agreement with previously published stu-
dies which demonstrated a high in vitro activity of this
drug for C. neoformans [17,22]. It has been demon-
strated that there are no trends towards higher MICs
for strains isolated from patients who failed to respond
to a given therapy compared to isolates from patients
who did not [23]. On the other hand, patient 4 was
infected with two different genotypes with similar
susceptibility profiles. Because the short time in between
each isolation it is suggestive that this was not a recur-
rent infection, it is possible that the patient was infected
simultaneously with both strains. Patients 2 and 5 had
three and two isolates respectively with similar suscept-
ibility patterns. In the first case only the CSF isolates
were genotypically similar. This might imply that this
patient was also infected simultaneously with more than
one strain however there might be a bias because mixed
infections in one sample of morphologically similar
cryptococci might have been missed. In the second case,
isolates differed in one marker and were thus considered
to be genetically related. These observations suggest
microevolution of C. neoformans during human infec-
tion. This process may allow the fungal population to
change and escape eradication by the immune system,
and thus cause chronic infections as suggested by Jain et
al. [24]. Patient 1 had two baseline isolates, from blood
and CSF, that had similar susceptibility but were genoty-
pically different. Since both genotypes were isolated
simultaneously this could mean that the patient was
infected with both strains at time of first sampling. As
has been stated before we might have missed mixed
infection at baseline because not all (morphologically)
similar colonies were studied. After more than three
months of fluconazole maintenance therapy, the patient
was re-admitted because signs and symptoms of relapse.
The CSF isolate obtained at that time had higher MIC
values for voriconazole and a different genotype com-
pared with the previous isolates. These findings suggest
two possibilities: i) the patient was re-infected with a
new strain during the maintenance therapy or ii) the
initial strains underwent genetic microevolution.
Figure 1 Details of the 19 C. neoformans isolates from 7 patients and relationship between the obtained genotypes. The numbers
below the genotype correspond to the number of repetitions observed in markers CNA2a, CNA2b, CNA2c, CNA3a, CNA3b, CNA3c, CNA4a,
CNA4b and CNA4c, respectively. A hyphen indicates that no result was obtained. The dendrogram is based on a categorical analysis using
UPGMA clustering. The scale bar indicates the percentage similarity.
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Cerebrospinal fluid from patient 7 remained microscopi-
cally (Indian ink) and culture positive during more than
5 months, despite antifungal therapy. Only the second
and third isolate showed the same genotype which was
different from the first and the fourth isolate. This could
be explained by simultaneous infection with more than
one strain or by re-infection with a new strain during
treatment which developed genetic changes over time.
This is corroborated by the increased MICs values for
fluconazole, itraconazole and voriconazole of the last
isolate.
Other authors have studied the molecular relationship
of C. neoformans isolates obtained from the same epi-
sode of infection or during a recurrent infection with
several different techniques [10,11,24-26]. Although the
obtained results are variable, most authors suggest that
persistence or recurrence of the infection is caused by
relapse rather than re-infection and/or microevolution
of the original isolate [20,25-28]. Multiple strain infec-
tion was rarely considered until a recent study reported
a high frequency of mixed infections in 20% of patients
with cryptococcal disease and speculated that multiple
strains could be exogenously acquired from the environ-
ment, either simultaneous or sequentially [29]. A bias
was entered in our study because only one colony was
selected for archiving from each sampling point
(because all growing colonies were morphologically
similar). Morphological similar colonies might have dif-
ferent genotypic backgrounds as has been shown
recently [29].
Conclusions
STR typing as presented in this study has not been lar-
gely used for Cryptococcus molecular characterization.
This new typing technique allowed the observation of
high genetic variability among the studied clinical iso-
lates keeping in mind the previous mentioned limitation
of this study and we confirm the observation of within-
host strain diversity [29]. Recurrence of infection in the
majority of these patients were not associated with drug
resistance but probably by co-infection with different
strains or strains genetically modified during the long
maintenance therapy.
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